vudalimab + docetaxel

Vudalimab + docetaxel is an investigational **combination therapy** being studied primarily for the treatment of advanced cancers including metastatic castration-resistant prostate cancer (mCRPC) and nonsquamous non-small cell lung cancer (NSCLC). **Vudalimab (XmAb20717)** is a humanized bispecific monoclonal antibody that simultaneously targets and inhibits **programmed cell death protein 1 (PD-1)** and **cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)**, crucial immune checkpoints involved in downregulating the immune response. By blocking these pathways, vudalimab is designed to unleash T-cell mediated anti-tumor activity while preferentially binding to cells that express both PD-1 and CTLA-4, aiming for more selective immune activation and potentially reducing toxicity compared with separate dual checkpoint blockade[2][4][6][7]. **Docetaxel** is a well-characterized cytotoxic taxane chemotherapy that inhibits microtubule depolymerization, causing cell cycle arrest and apoptosis in dividing tumor cells. The rationale for combining vudalimab with docetaxel is to enhance anti-tumor efficacy by combining immune checkpoint inhibition with direct cytotoxic chemotherapy, exploiting both tumor cell killing and immune-mediated anti-tumor responses. Early-phase studies suggest potential activity but also highlight tolerability challenges, prompting ongoing protocol optimizations[4].